Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Oncogenic fusion proteins, resulting from chromosomal rearrangements, are key drivers of cancer development.
• These fusion proteins represent critical targets for novel cancer therapies.
• Small molecular inhibitors offer a targeted approach to combat cancers with these specific molecular alterations.

Purpose of the Study:

• To provide a comprehensive review of small molecular inhibitors targeting oncogenic fusion proteins.
• To elucidate the mechanisms of action and clinical progress of these targeted therapies.
• To inform the medicinal community and accelerate drug discovery for fusion protein-driven cancers.

Main Methods:

• Literature review of current research on small molecular inhibitors and oncogenic fusion proteins.
• Analysis of the rationale, mechanisms of action, and challenges in targeting fusion proteins.
• Summary of clinical trial data and progress in the field.

Main Results:

• Small molecular inhibitors demonstrate significant potential in selectively targeting oncogenic fusion proteins.
• Various inhibitors targeting specific fusion proteins have shown promising clinical outcomes.
• Challenges include resistance mechanisms and off-target effects, requiring further research.

Conclusions:

• Small molecular inhibitors are a viable and evolving therapeutic strategy against fusion protein-driven cancers.
• Continued research and development are essential to overcome challenges and optimize treatment efficacy.
• This review provides a valuable resource for advancing targeted cancer therapy discovery programs.